#amicus therapeutics

[reportwire]

Carl Icahn Slashes Stake in Occidental Petroleum

Carl Icahn Slashes Stake in Occidental Petroleum

Text size These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Feb. 24 through March 2, 2022. Source: InsiderScore.com Activist…

View On WordPress

[alphst]

Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot

Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot

— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $ per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share last year.

— Total revenues more than doubled from last year to $182.2 billion, compared to estimates of $52.33 million

— Total operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018

View On WordPress

[stockcalc]

Array BioPharma (ARRY:NAS) Fundamental Valuation Report

Array BioPharma (ARRY:NAS) Fundamental Valuation Report

Fundamental Valuation Report

Array BioPharma(ARRY:NAS) Healthcare:Biotechnology

This Report was generated using…

View On WordPress

[ustribunenews-blog]

Amicus Therapeutics, Inc. (Nasdaq:FOLD) Dips To New 52 Week Low

Amicus Therapeutics, Inc. (Nasdaq:FOLD) Dips To New 52 Week Low

Amicus Therapeutics, Inc. (Nasdaq:FOLD)

December 22nd, 2018 Amidst falling markets Amicus Therapeutics, Inc. finished Friday’s trading session down 5.95%, a $0.53 decrease to close on $8.38. As well as the drop in value, Amicus Therapeutics, Inc. hit a new 52 week low of $8.32, breaking the previous low of $8.77 from earlier this month. Despite the drop in value, trading volumes were solid at…

View On WordPress

[ustribunenews-blog]

(Nasdaq:FOLD) Amicus Therapeutics, Inc. Hits 52 Week Low

(Nasdaq:FOLD) Amicus Therapeutics, Inc. Hits 52 Week Low

Amicus Therapeutics, Inc. (Nasdaq:FOLD)

December 6th, 2018 Amicus Therapeutics, Inc. finished up $0.44 Thursday, up 4.44%, closing at $10.36. Despite ending the day higher, Amicus Therapeutics, Inc. hit a new 52 week low of $9.65. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be 0.61. (mor…

View On WordPress

[amcrasto]

FDA approves new treatment Galafold (migalastat) for a rare genetic disorder, Fabry disease

FDA approves new treatment Galafold (migalastat) for a rare genetic disorder, Fabry disease

FDA approves new treatment for a rare genetic disorder, Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation determined to be responsive (“amenable”) to treatment with Galafold based on laboratory data. Fabry…

View On WordPress

[ustribunenews-blog]

Amicus Therapeutics, Inc. (Nasdaq:FOLD) Breaks 52 Week High Record Of $17.62

Amicus Therapeutics, Inc. (Nasdaq:FOLD) Breaks 52 Week High Record Of $17.62

Amicus Therapeutics, Inc. (Nasdaq:FOLD)

June 21st, 2018

Amicus Therapeutics, Inc. closed Wednesday up 1.67%, a $0.28 increase to close on $17.09. In addition it hit a new 52 week high of $17.62. While it is positive news the stock ended higher, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty.

FOLD outperformed the rest of the Healthcare…

View On WordPress

[steinmeyerlaw-blog]

Amicus Therapeutics (FOLD)  claims it manufactures drugs that treat human genetic diseases, including Fabry, Gaucher and Pompe disease. Fabry disease, which affects about 1 in 40,000 to 60,000 males, can produce pain, gastrointestinal problems and hearing loss, and in some cases can lead to kidney damage, heart attack and stroke. Clearly, affiliates of Glaxo Smithkline didn’t want to stick…

View On WordPress